Pulmonary sporotrichosis: review of treatment and outcome
Related Experiment Video
Updated: Oct 13, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
Published on: March 1, 2024
Abstract:
Four culture-documented cases of pulmonary sporotrichosis, three primary infections and one with multisystem involvement, are presented. Two of these patients are the first reported cases of primary lung disease treated with ketoconazole. This antifungal agent appears to be ineffective in eradicating this infection. The four cases, as well as a review of the literature, illustrate several important aspects of this rare disease. Pulmonary sporotrichosis is most commonly found in males with a history of alcohol abuse who are between the ages of 30 and 60. The infection is usually confined to the parenchyma of the lung but can involve hilar and mediastinal lymph nodes, pleura, skin, subcutaneous tissue, and joints. All but two cases have been reported in the United States, and the majority reside within states bordering the Missouri or Mississippi rivers. Direct occupational or environmental exposure appears to be an important predisposing risk factor. The onset of the disease is insidious, presenting in a manner similar to many other granulomatous or neoplastic diseases. Tuberculosis is the most common suspected diagnosis before confirmation of sporotrichosis. The chest radiograph most commonly demonstrates upperlobe cavitary disease with surrounding parenchymal infiltrates. The diagnosis can be suspected with high serologic titers or skin-test positivity, but needs to be confirmed by culture. The organism can usually be grown from sputum, as well as routine bronchoscopic procedures, open-lung biopsy specimens or pleural fluid. Histologic examination shows granulomas of both the caseating and noncaseating varieties. Frequently, organisms can be seen in necrotic areas of the lung tissue by diastase-modified GMS or PAS staining. Staining by direct fluorescent antibody technique can also be done and appears to be highly specific. Treatment is controversial, but total surgical resection of diseased lung as well as a perioperative regimen of SSKI or amphotericin B appears to be the most efficacious therapy. Medical therapy alone with SSKI or amphotericin B may be useful in selected cases but has been disappointing in the majority of reports. The imidazoles are usually ineffective, and the search for more effective medical therapy continues.
Insights
Pulmonary sporotrichosis is a rare fungal infection often misdiagnosed. Ketoconazole is ineffective, and treatment may require surgery or amphotericin B.
Area of Science:
- Mycology
- Pulmonology
- Infectious Diseases
Background:
- Pulmonary sporotrichosis is a rare fungal infection caused by Sporothrix schenckii.
- It primarily affects middle-aged males with a history of alcohol abuse.
- Geographic distribution is concentrated in the United States, particularly along the Missouri and Mississippi rivers.
Observation:
- The study presents four cases of pulmonary sporotrichosis, including primary lung infections and multisystem involvement.
- Two cases represent the first reported instances of primary pulmonary disease treated with ketoconazole.
- Clinical presentation is insidious, mimicking granulomatous or neoplastic diseases, with tuberculosis being a common initial diagnosis.
Findings:
- Ketoconazole demonstrated ineffectiveness in eradicating pulmonary sporotrichosis.
- Radiographic findings typically include upper-lobe cavitary disease with parenchymal infiltrates.
- Diagnosis relies on culture confirmation, with positive serologic titers or skin tests providing supportive evidence. Histopathology reveals granulomas, and specific stains can identify the organism.
Implications:
- Current medical therapies, including imidazoles like ketoconazole, appear largely ineffective for pulmonary sporotrichosis.
- Surgical resection combined with perioperative amphotericin B or potassium iodide (SSKI) is suggested as the most effective treatment.
- Further research is needed to identify more effective medical treatments for this challenging infection.
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
